Two live-attenuated, cold-passaged (cp), temperature-sensitive (ts) candidate vaccines, designated cpts530/1009 and cpts248/955, were attenuated, genetically stable, and immunogenic in chimpanzees and were highly attenuated for human adults. In respiratory syncytial virus (RSV) -seropositive children, cpts530/1009 was more restricted in replication than cpts248/955. In seronegative children, 10 4 pfu of cpts248/955 was insufficiently attenuated, and a high titer of vaccine virus was shed (mean peak titer, 10 4.4 pfu/mL), whereas 10 4 pfu of cpts530/1009 was relatively attenuated and restricted in replication (mean peak titer, 10 2.0 pfu/mL). At a dose of 10 5 pfu, cpts530/1009 was immunogenic in seronegative children (geometric mean titer of RSV neutralizing antibodies, 1:724). Transmission of either vaccine to seronegative placebo recipients occurred at a frequency of 20% -25%. Of importance, vaccine viruses recovered from chimpanzees and humans were ts. In contrast to previous studies, this study indicates that live attenuated RSV vaccines that are immunogenic and phenotypically stable can be developed. Additional studies are being conducted to identify a live RSV vaccine that is slightly more attenuated and less transmissible than cpts530/1009.
Respiratory syncytial virus (RSV) is the leading cause of
antigenically divergent RSV subgroups A and B. Finally, it is likely that infants will need to be immunized several times to viral respiratory illness in infants and children throughout the achieve a satisfactory level of immunity since even a single world (reviewed in [1] ) and is an important cause of severe infection with wild type (wt) RSV does not completely protect respiratory illness in the elderly [2] and in immunocomproagainst subsequent RSV-associated LRI [9, 10] . mised patients [3] . In the United States, RSV infections account Efforts to produce a safe and effective RSV vaccine have for Ç90,000 hospitalizations of children each year [4] .
been underway for ú30 years. Early attempts yielded a formaThe importance of RSV as a respiratory pathogen makes lin-inactivated vaccine that produced enhanced disease in some RSV vaccine development a priority [5] . Since an effective immunized RSV-naive infants when they were naturally invaccine will need to provide protective immunity against RSVfected with wt RSV during the subsequent RSV season [11, associated lower respiratory tract illness (LRI) in young infants, 12]. More recently, an RSV fusion (F) subunit vaccine has RSV immunization will need to be initiated in the first month been produced that may prove useful in the elderly [13] but is of life. It may be difficult to immunize this population effecunlikely to be administered to young infants. Adenovirus and tively for several reasons. Young infants may respond poorly vaccinia virus recombinants containing the RSV F and attachto an RSV vaccine because of immunologic immaturity and ment (G) glycoproteins have also been developed but were not because maternally derived antibody may interfere with the sufficiently immunogenic in chimpanzees to warrant clinical immune response to the vaccine [1, 6 -8] . Infants will also evaluation [14 -16] . need to be immunized with a vaccine that protects against the Live RSV vaccines might provide the best alternative for immunizing young infants. A live vaccine would mimic natural infection, induce a balanced cellular and humoral immune response, and be unlikely to produce enhanced disease [6] . In or underattenuated in young children [18 -21] , and those that were temperature-sensitive (ts) did not retain this phenotype was insured by the use of identical protocols and challenge virus cpRSV, a non-ts strain, contained mutations that restricted viral suspensions. In addition, inoculation, sampling, and clinical scorreplication in adults and RSV-seropositive children but was ing procedures were performed by the same individuals in each insufficiently attenuated for RSV-seronegative children [19] . study. Following inoculation of virus, nasopharyngeal swab specicpRSV was subjected to two rounds of chemical mutagenesis, mens were collected while animals were under ketamine anesthesia and ts mutant derivatives (referred to as cpts) were generated for quantitation of the amount of virus shed on days 1-10, 13, [23 -25] . It was hoped that the non-ts attenuating mutations 16 , and 20, and tracheal lavage specimens were collected on days present in the cpRSV parent virus would act in concert with 2, 4, 6, 8, 10, 13, 16 , and 20, as described previously [15] . Virus the ts mutations to yield attenuated, genetically stable vaccines. present in the respiratory tract secretions was quantified by plaque Several cpts RSV mutants were subsequently shown to be titration at 32ЊC, 39ЊC, and 40ЊC on HEp-2 cells as previously restricted in replication in BALB/c mice and in chimpanzees described. The amount of rhinorrhea was estimated daily and assigned a score of 0 to 4 by an experienced observer (0 Å none, 1 [23, 24] . The ts phenotype of two of these mutants was more Å trace, 2 Å mild, 3 Å moderate, 4 Å severe [29] õ1 year of age. Ninety-nine adults participated in these studies: 44 received the RSV wt A2 virus, 20 each received the cpRSV or the cpts248/955 viruses, and 15 received cpts530/1009. The health of the adult volunteers was assessed as previously described [29] .
Materials and Methods
The wt RSV A2 virus was evaluated in the Johns Hopkins Viruses. The isolation and characterization of wt RSV strain University Center for Immunization Research (CIR) isolation unit. A2, of cpRSV, and of the ts mutants 248/955 (shutoff temperature, Volunteers were given 10 3.9 pfu of RSV A2 wt virus in 1 mL 37ЊC) and 530/1009 (shutoff temperature, 36ЊC) have been deintranasally. Nasal washes to quantitate virus shedding were perscribed [24] [25] [26] [27] . Each of these ts mutants was derived indepenformed daily, once prior to inoculation and for 10 days after. dently from cpRSV by serial mutagenesis with 5-fluorouracil in Volunteers were examined each day, and their temperatures and Vero cell monolayer cultures. The ts mutants were biologically vital signs were recorded every 6 h during the 13-day isolation cloned by three plaque-to-plaque passages and amplified by four period. Vaccine strains were evaluated in outpatient studies at the passages to prepare the vaccine pools. The wt RSV strain A2 CIR. Volunteers who received 10 5 pfu of cpRSV, cpts248/955, or (designated lot RSV M6) was prepared in MRC-5 cell monolayer cpts530/1009 intranasally were examined on the day of inoculation cultures, and each of the progeny strains (cpRSV, lot A-11; and on days 4-8 following inoculation. On each study day (0-cpts248/955, lot A-10; and cpts530/1009, lot A-16) were prepared 10), volunteers recorded their own oral temperatures twice and in qualified Vero cell monolayer cultures. The cpRSV lot A-11 reported any respiratory or febrile illness to the study nurse. All differed from the previously evaluated cpRSV [27] in that it was subjects who reported illness were examined by a study investigabiologically cloned by three plaque-to-plaque passages in MRC -5 tor. cell monolayer cultures. This cloned preparation of cpRSV served Clinical studies of children. After cpts248/955 and cpts530/ as the immediate parent for the cpts derivative viruses. Virus sus-1009 were shown to be well tolerated in adults, these strains were pensions for clinical trials were produced and found to be free of evaluated in randomized, double-blind, placebo-controlled phase adventitious agents by Louis Potash (Dyncorp/PRI, Bethesda, I trials in infants and children 6-60 months of age at the CIR MD). The titers of the wt RSV A2 strain and of cpRSV, cpts248/ and at the Vanderbilt University Vaccine Center (VVC). Ninety 955, and cpts530/1009 were 10 3.9 , 10 5.8 , 10
5.9
, and 10 5.5 pfu/mL, children were enrolled in these phase I safety and immunogenicity respectively. When necessary, the virus suspensions were diluted studies: 40 participated in studies of cpts248/955 and 50 in studies in L-15 medium (BioWhittaker, Walkersville, MD) immediately of cpts530/1009. Children were eligible to participate in these prior to use. studies if they were healthy and if all other household members Studies in chimpanzees. Young male or female chimpanzees and day care contacts were §1 year of age. Prior to enrollment, (Pan troglodytes) weighing 8.8-10.4 kg were pair-housed in large children were screened for level of RSV serum neutralizing antiglass isolator suites and maintained as described previously [28] .
body by a complement-enhanced, 60% plaque-reduction neutralThe animals given cpts248/955 were on loan from the University of ization assay [30] ; those with titers ú1:40 were considered RSVTexas MD Anderson Cancer Center (Bastrop). These chimpanzees seropositive. Both vaccines were initially tested at a dose of 10 5 lacked detectable serum neutralizing antibodies to RSV A2 (titer pfu in seropositive children and tested subsequently at a dose of õ1:10). Four seronegative chimpanzees were inoculated with 10 4 pfu (cpts248/955 strain) or at 10 4 or 10 5 pfu (cpts530/1009 cpts248/955 by both the intranasal and intratracheal routes with a strain) in seronegative children. Each subject received 0.5 mL of dose of 10 4 pfu in a 1-mL inoculum at each site. Data from similar vaccine or placebo intranasally. In the pediatric studies, the ratio animals that received wt RSV strain A2, cpRSV, and cpts530/ of vaccinees to placebo recipients was Ç2:1. Seropositive study 1009 were described previously [23, 25] and are presented here participants were examined 2 days before inoculation and for 9 days after. Seronegative study participants were examined 2 days for the purpose of comparison. The comparability of the studies before and on days 1-9, 11, 14, 16, 18, 21, and 23 after inocula-RSV F or G glycoprotein were detected. In these instances, the ELISAs for both F and G glycoproteins were repeated and, if the tion; interval symptom histories were obtained from parents on days when the children were not examined. Children were obresponse was confirmed, these individuals were considered to have been infected with the candidate vaccine virus. Isolated nasal wash served for 1-2 h at the CIR and for 6-10 h at the VVC in a playroom setting on each study day. Respiratory and febrile illantibody responses to RSV F or G glycoprotein were not considered definitive evidence of infection with vaccine virus. nesses were defined as fever (rectal temperature, §38.1ЊC), upper respiratory tract illness (URI; rhinorrhea or pharyngitis for §2
RSV antibody titers were expressed as reciprocal mean log 2 . The Mann-Whitney U test (two-tailed) was used to compare mean days), LRI (persistent wheezing or pneumonia), and cough (on §2 consecutive days) [31] .
titers between groups. Rates of illness among vaccinees and placebo recipients were compared by two-tailed Fisher's exact test. To assess the long-term safety of the cpts 248/955 and 530/1009 candidate vaccines, seronegative infants and children enrolled in these trials were followed through the subsequent RSV season. A group of RSV-seronegative children who did not receive vaccine
Results
or placebo were recruited as additional control subjects for this phase of the study. Children who participated in surveillance were
Response of RSV-seronegative chimpanzees to wt RSV A2, suggesting that it would be safe to evaluate these vaccines in obtained on each day of observation from all subjects who particiclinical trials. RSV cpts248/955 recovered from nasopharynpated in these studies. Fresh undiluted nasal wash specimens were titered by plaque assay on HEp-2 cell monolayer cultures maingeal specimens (n Å 30) and tracheal lavage specimens (n tained under a semisolid overlay at 32ЊC as previously described, Å 5) failed to produce plaques at 40ЊC, indicating that the and results were expressed as log 10 pfu/mL [25] . Nasal wash samcpts248/955 candidate vaccine, like the previously evaluated ples were also inoculated into tubes containing Vero and HEpcpts530/1009 candidate vaccine, retained the ts phenotype after ). In contrast, cpts530/1009 infected few vaccinees and was not recovered from any seropositive the vaccinees who received cpts248/955 and 31% of those who received cpts530/1009. Nasal antibody responses to eichild, indicating that it was more attenuated than cpts248/955 for seropositive children. The absence of LRI in seropositive ther candidate vaccine were detected less frequently in these seropositive children. A single placebo recipient in the recipients of the cpts248/955 and 530/1009 candidate vaccines suggested that it was safe to continue the evaluation of these cpts248/955 vaccine study developed a 4-fold rise in serum antibody titer to the RSV F glycoprotein, which might have cpts viruses in RSV-seronegative children. NOTE. Six-to 60-month-old RSV-seropositive children and 6-to 36-month-old RSV-seronegative children were enrolled in these studies. For purposes of this study, seropositive children were those with RSV serum plaque-reduction neutralizing antibody titers ú1:40. Infection was defined as described in text. URI, upper respiratory tract illness; LRI, lower respiratory tract illness. Duration of shedding is defined as last day on which vaccine virus was recovered.
* (table 2) . Eighty-eight percent of seronegative infants and children observed in other study participants. The cpts530/1009 mutant was apparently transmitted to this placebo recipient, shed vaccine virus (mean peak titer, 10 4.4 pfu/mL). Respiratory or febrile illness or otitis media associated with shedwho shed 10 1.7 pfu of vaccine virus on a single day (day 16) that did not coincide with her LRI (days 18 -20) . URI, lowding of cpts248/955 was observed in all infected children, 1 of whom also had a viral enanthem consistent with enterograde fever, and otitis media occurred frequently but at approximately the same rate in vaccinees and placebo recipivirus infection. One child who received cpts248/955 had 3 days of LRI (wheezing) associated with viral shedding (figents (table 2) . The cpts248/955 and 530/1009 candidate vaccines were ure 1). This child, who was treated as an outpatient, received nebulized bronchodilators and oral bronchodilators and stehighly immunogenic in RSV-seronegative children (table 3) . Rises in neutralizing or F or G antibody titers were detected roids and recovered uneventfully. Because the cpts248/955 candidate vaccine retained the capacity to cause LRI, its in 88% of those who received 10 4 pfu of cpts248/955 and all of those who received 10 5 pfu of cpts530/1009. Nasal clinical evaluation was terminated. This virus was also transmitted to a placebo recipient, who shed virus (10 3.7 pfu/mL) antibody responses were detected less frequently than serum antibody responses in these children, perhaps because of the and had rhinorrhea and cough on days 21 -23.
At a dose of 10 4 pfu, RSV cpts530/1009 was more attenuinsensitivity of the assay as compared with that of serologic assays. ated than cpts248/955. The mean peak titer of virus shed by seronegative vaccinees was 10 2.0 pfu/mL, which was less A total of 23 seronegative vaccinees (8 of whom received cpts248/955 and 15 of whom received cpts530/1009) and 64 than that shed by seronegative recipients of the cpts248/955 candidate vaccine (P Å .01, Mann-Whitney U test). LRI was unvaccinated children (13 placebo recipients and 51 control / 9d3b$$de06 10-30-97 12:14:02 jinfa UC: J Infect subjects) participated in RSV surveillance. Twelve (52%) of are restricted in replication at core human body temperature the vaccinees and 31 (48%) of the unvaccinated subjects were has been used successfully to generate cold-adapted (ca) ts infected with wt RSV during surveillance. Of the infected vacvaccines against influenza virus and parainfluenza virus type cinees, all had URI, 2 had fever, 2 had otitis media, and one 3 (reviewed in [34]), [35] . Earlier attempts to develop RSV had LRI. The single subject with LRI (wheezing and crackles vaccines that were either cp or ts were initially abandoned on auscultation) was a recipient of cpts530/1009 who did not because of residual virulence for RSV-seronegative infants and shed vaccine virus but had developed a neutralizing antibody because of the genetic instability of the RSV ts-1 mutant [1] . response to RSV. Of the infected unvaccinated subjects, all Recently, cpRSV was further mutagenized to generate a series had URI, 11 had fever, 8 had otitis media, and 3 had LRI (all of cpts vaccine candidates that were shown to be attenuated 3 children wheezed; 1 also had crackles on auscultation). Thus, and genetically stable in mice and seronegative chimpanzees there was no evidence of enhanced disease when recipients of [15, 23 -25] . The cpRSV evaluated in this study was a biologithese live RSV candidate vaccines were infected with wt RSV.
cally cloned derivative of the cpRSV previously evaluated in Phenotypic stability of the cpts248/955 and 530/1009 vacthe 1960s and 1970s. In the present study, we found that the cines. Despite a moderate to high level of replication in the cloned cpRSV, the immediate parent of the cpts vaccines, was upper respiratory tracts of RSV-seropositive and -seronegative attenuated in adults. This indicates that the biologically cloned children, the cpts248/955 candidate vaccine retained the ts phecpRSV contains non-ts attenuating mutations that should be notype: Each of 40 nasal wash specimens containing virus present in its cpts derivatives. Indeed, the cpts viruses seproduced plaques at 32ЊC but not at 40ЊC. Similarly, virus quenced to date contain the five nucleotide mutations [36] present in each of 71 specimens from vaccinees infected with present in the biologically cloned cpRSV parent virus. Thus, the cpts530/1009 candidate vaccine retained the ts phenotype.
one or more of these non-ts mutations attenuate cpRSV for The efficiency of plaque formation of virus present in the nasal chimpanzees and adults. washes of 5 cpts530/1009 vaccinees (table 4) indicated that
In this study, we also demonstrated that the cpRSV, cpts248/ little drift in the level of temperature sensitivity occurred during 955, and cpts530/1009 viruses showed a progressive increase viral replication in fully susceptible children over an interval in attenuation for seronegative chimpanzees and adults. Howof 9 -14 days.
ever, the cpts248/955 candidate vaccine was not sufficiently attenuated for fully susceptible (i.e., RSV-seronegative) chilDiscussion dren because it was shed in large quantities from the upper respiratory tract, temporally associated with rhinorrhea in 6 The strategy of passaging virus at low temperature to yield mutants that replicate efficiently at suboptimal temperature but children and with LRI in 1 child, and transmitted to a placebo / 9d3b$$de06 10-30-97 12:14:02 jinfa UC: J Infect poliovirus vaccines, will retain the ability to spread to contacts, † Small plaque phenotype (õ50% wild type plaque size at 32ЊC).
and studies of future live RSV candidate vaccines will need to address this possibility. The stability of the ts phenotype of the cpts248/955 and recipient. These studies suggest that RSV candidate vaccines, such as cpts248/955, that replicate to high titer in seropositive 530/1009 candidate vaccines was assessed by determining the efficiency of plaque formation of virus present in 40 nasal wash children may not be sufficiently attenuated for seronegative children. Evaluation of the cpts530/1009 candidate vaccine in specimens of those who received the 248/955 candidate vaccine and 71 nasal wash specimens of those who received the 530/ seropositive children showed that this virus was more restricted in replication and more attenuated than cpts248/955. The clini-1009 candidate vaccine. None of the virus present in the nasal washes produced plaques at 40ЊC, indicating that the ts phenocal evaluation of cpts530/1009 in seronegative children was complicated by concurrent adenovirus infection in 4 subjects type was maintained despite vigorous replication of these viruses in the upper respiratory tracts of RSV-seronegative sub-(and LRI in 2 subjects infected with both viruses); however, LRI was only observed in the children who shed adenovirus, jects. This is the first evidence that live RSV candidate vaccines
